Stockscreener 앱 받기
38.86
9.74%
3.45
시장 영업 전:
38.69
-0.17
-0.44%
전일 마감가:
$35.41
열려 있는:
$35.1
하루 거래량:
4.46M
Relative Volume:
0.98
시가총액:
$4.39B
수익:
-
순이익/손실:
$-99.15M
주가수익비율:
-41.78
EPS:
-0.93
순현금흐름:
$-74.25M
1주 성능:
+7.14%
1개월 성능:
+12.21%
6개월 성능:
+43.93%
1년 성능:
-24.16%
1일 변동 폭
$34.80
$39.99
1주일 범위
$33.81
$39.99
52주 변동 폭
$18.92
$52.58
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
VKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
38.86 | 4.00B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-29 | 개시 | Canaccord Genuity | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
What's Up With The Jump In Viking Therapeutics Stock? - Benzinga
Will Viking Therapeutics Inc. stock outperform international peersWeekly Profit Recap & Smart Allocation Stock Tips - Newser
The FDA Is Shaking Things Up; Biotech, Research Stocks Diverge - Investor's Business Daily
How Viking Therapeutics Inc. (1VT) stock expands through international marketsTrade Ideas & Weekly Breakout Opportunity Watchlist - Newser
What consensus target says about Viking Therapeutics Inc. (1VT) stockMarket Performance Summary & Daily Entry Point Alerts - Newser
Will Viking Therapeutics Inc. stock benefit from sector rotationJuly 2025 Big Picture & Low Drawdown Trading Techniques - Newser
Viking Therapeutics Meets 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
How Viking Therapeutics Inc. stock responds to policy changesBuy Signal & Growth Oriented Trade Recommendations - Newser
Viking Therapeutics Stock Gains Momentum on Clinical Progress - AD HOC NEWS
42,134 Shares in Viking Therapeutics, Inc. $VKTX Purchased by Scotia Capital Inc. - MarketBeat
Why Viking Therapeutics Inc. stock appeals to analysts2025 Pullback Review & Stock Portfolio Risk Management - Newser
Will Viking Therapeutics Inc. (1VT) stock deliver compounding returnsJuly 2025 Setups & Expert Curated Trade Setups - Newser
What margin trends mean for Viking Therapeutics Inc. stockEntry Point & Fast Moving Market Watchlists - Newser
Is There a Future for Viking Therapeutics? - AOL.com
The Bull Case For Viking Therapeutics (VKTX) Could Change Following Early Completion and Positive Data in Obesity Trial - simplywall.st
Viking Therapeutics Emerges as a Prime Acquisition Candidate Amid Obesity Drug Advancements - AD HOC NEWS
XTX Topco Ltd Acquires Shares of 36,199 Viking Therapeutics, Inc. $VKTX - MarketBeat
Why Viking Therapeutics Inc. (1VT) stock attracts HNW investorsQuarterly Trade Report & Proven Capital Preservation Methods - Newser
VKTX Stock Rises 34% in Three Months: Here's What You Should Know - sharewise.com
Viking Therapeutics Emerges as a Prime Acquisition Target Following Trial Success - AD HOC NEWS
(VKTX) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Viking Therapeutics Stock Gains Momentum on Clinical Trial Milestone - Ad-hoc-news.de
Assessing Viking Therapeutics (VKTX) Valuation After Recent Share Price Recovery - Yahoo Finance
Ensign Peak Advisors Inc Trims Stake in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics (VKTX): Evaluating Valuation After Key Phase 3 Obesity Trial Milestone and New Clinical Data - simplywall.st
Viking Therapeutics: A Clash of Convictions - Ad-hoc-news.de
SG Americas Securities LLC Makes New $379,000 Investment in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating - Finviz
What drives Viking Therapeutics Inc stock pricePrice Channel Trading & Small Entry Cost Trading - earlytimes.in
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - Finviz
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Is Viking Therapeutics Inc. stock a good choice for value investorsRisk Management & Low Drawdown Momentum Ideas - BỘ NỘI VỤ
Why Viking Therapeutics Inc. stock remains undervaluedJuly 2025 Sentiment & Daily Stock Trend Watchlist - BỘ NỘI VỤ
Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 - Finviz
Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 - The Motley Fool
Viking Therapeutics: A Stock at a Crossroads - Ad-hoc-news.de
Market Catalysts: What momentum indicators show for Viking Therapeutics Inc. stockJuly 2025 Sentiment & High Return Trade Guides - moha.gov.vn
Viking Therapeutics to Participate at the Piper Sandler 37th Ann - GuruFocus
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference - Yahoo Finance
Viking Therapeutics (VKTX) Balances Rising R&D Costs With Clinical Progress: Is the Risk Worth the Potential? - Yahoo Finance
Viking Therapeutics (VKTX) Is Down 9.3% After Phase 3 Trial Milestone and Rising LossesHas The Bull Case Changed? - simplywall.st
VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave? - ts2.tech
A Closer Look at Viking Therapeutics (VKTX) Valuation Following Recent Share Price Momentum - Sahm
Viking Therapeutics Stock: Clinical Trial Momentum Builds Substantial Upside - Ad-hoc-news.de
Viking Therapeutics Stock: A Turning Point Emerges - Ad-hoc-news.de
2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon - Finviz
Viking Therapeutics Stock: A Transformative Week for the Biotech Firm - Ad-hoc-news.de
Viking Therapeutics (VKTX) Up 1% Since Last Earnings Report: Can It Continue? - sharewise.com
Viking Therapeutics concludes enrolment in Phase III trial of obesity therapy - Clinical Trials Arena
3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential - Finviz
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.10%
1.10%
자본화:
|
볼륨(24시간):